All news

BSX holds Buy as analyst target sees 42.7% upside

Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash

RBC Capital analyst Kendall Au maintained a Buy rating on Boston Scientific (BSX) with a $70.00 price target. This aligns with a general "Strong Buy" consensus among analysts, predicting a 35.51% upside. The company recently reported strong quarterly revenues of $5.44 billion and a net profit of $907 million, alongside positive insider sentiment with increased insider stock purchases.

Read original source

BSX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.